Reply to letter regarding article, "evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs".
Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College, London, UK.
Blerina
B
Ahmetaj-Shala
Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College, London, UK.
Nicholas S
NS
Kirkby
The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK.
Rebecca
R
Knowles
Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College, London, UK, King Fahad Cardiac Center, King Saud University, Riyadh, Saudi Arabia.
Malak
M
Al'Yamani
Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College, London, UK, King Fahad Cardiac Center, King Saud University, Riyadh, Saudi Arabia.
Sara
S
Mazi
MRC Clinical Sciences, Imperial College London, Nitric Oxide Signalling Group, Hammersmith Hospital, London, UK.
Zhen
Z
Wang
The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK.
Arthur T
AT
Tucker
School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.
Louise S
LS
Mackenzie
The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK.
Paul C J
PC
Armstrong
Institute of Clinical Pharmacology, Johann Wolfgang Goethe-University, Frankfurt, Germany.
Rolf M
RM
Nüsing
MRC Clinical Sciences, Imperial College London, Nitric Oxide Signalling Group, Hammersmith Hospital, London, UK.
James A P
JA
Tomlinson
The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK.
Timothy D
TD
Warner
MRC Clinical Sciences, Imperial College London, Nitric Oxide Signalling Group, Hammersmith Hospital, London, UK.
James
J
Leiper
Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College, London, UK.
Jane A
JA
Mitchell
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001120:Arginine / Q000031:analogs & derivatives*; D002318:Cardiovascular Diseases / Q000097:blood*; D051546:Cyclooxygenase 2 / Q000172:deficiency*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male
D000893:Anti-Inflammatory Agents; D052246:Cyclooxygenase 2 Inhibitors; D001120:Arginine; D051546:Cyclooxygenase 2